EDITFORCE AND MITSUBISHI TANABE PHARMA ENTER INTO LICENSE AGREEMENT
EditForce, Inc. (Headquarters: Fukuoka, President and CEO: Takashi Ono; hereafter “EditForce”) has entered into a License Agreement with Mitsubishi Tanabe Pharma Corporation (Headquarters: Osaka, Representative Director, Hiroaki Ueno; hereafter “MTPC”) to research, develop and commercialize potential gene therapy products for a specific target disease in the field of CNS by utilizing EditForce’s proprietary PPR protein platform technology.
In this alliance,MTPC and EditForce aim to create potential novel pharmaceuticals for the specific CNS disease by utilizing the drug R&D know-how and global business experience of MTPC and the novel biotechnology of EditForce.
For more details, please see EDITFORCE AND MITSUBISHI TANABE PHARMA ENTER INTO LICENSE AGREEMENT (PDF)
Archives